Brainstorm Cell Therapeutics (NASDAQ:BCLI)‘s stock had its “buy” rating restated by Maxim Group in a research note issued to investors on Tuesday, AnalystRatings.com reports. They currently have a $9.00 price objective on the biotechnology company’s stock. Maxim Group’s price target would suggest a potential upside of 126.70% from the stock’s previous close.
The analysts wrote, “Brainstorm reported 1Q19 with a net loss of ~($5M) and $6.2M in cash on the balance sheet, excluding commitments from the CIRM and IIA grants of a combined $4M.””
Shares of NASDAQ:BCLI opened at $3.97 on Tuesday. Brainstorm Cell Therapeutics has a 1-year low of $2.92 and a 1-year high of $5.35. The company has a current ratio of 0.97, a quick ratio of 1.65 and a debt-to-equity ratio of 9.34.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Featured Article: Recession
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.